Moreover, early subcutaneous injection of GA in APP/PS1 mice, a model of Alzheimer’s disease (AD), delayed disease progression, reduced amyloid beta plaque burden, regulated neuroinflammation, promoted neuroprotection, and induced dendritic-like microglia [18,19]. The gene discussed is APP; the disease is Alzheimer disease.